Recruiting
Phase 1

Fluorodopa F 18

Sponsor:

Cook Children's Health Care System

Code:

NCT02021604

Conditions

Congenital Hyperinsulinism

Insulinoma

Eligibility Criteria

Sex: All

Age: 0 - 18

Healthy Volunteers: Not accepted

Interventions

Fluorodopa F 18

Study Details

Brief summary:

Low blood sugars are known to cause brain damage in newborn babies. One of the most common causes of low blood sugars persisting beyond the new born period is a condition called congenital hyperinsulinism (HI). This is a disease whereby the pancreas secretes too much insulin and causes low blood sugars. Twenty to forty percent of these babies will have brain damage. There are two forms of this disease. In one form only a small part of the pancreas makes too much insulin (focal HI) and in the other, the whole pancreas make too much insulin (diffuse HI). Another very similar disease is insulinoma which occurs after birth, but also causes hyperinsulinism. If a surgeon could know which part of the pancreas has the focal lesion he could remove it and cure the patient.

The purpose of this study is to investigate whether a new investigational drug called Fluorodopa F 18, when used with a PET scan, can find the focal lesion and guide the surgeon to remove it, thus curing the patient and preventing further brain damage.

Conditions

Congenital Hyperinsulinism

Insulinoma

Study ID

NCT02021604

Start date

Oct 9, 2013

Status verified date

Jul, 2024

Completion date

Jun, 2028

Anticipated

Primary completion date

Jan, 2028

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 18

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Patients with HI attending the Cook Children's Congenital Hyperinsulinism Center and being treated by an Endocrinologist which may be the PI or a partner of this clinician.
  • The patient's Endocrinologist has determined that the patient cannot be safely managed with standard medical therapy (failed) and surgery is recommended to prevent future episodes of severe hypoglycemia and preserve brain function. Failure of medical therapy is defined as both:

  • Hypoglycemia (blood glucose <70 m/dL) on a single measure despite the use of anti-hypoglycemic medications, if applicable to the individual patient, including and limited to diazoxide or octreotide
  • Inability to fast, defined as the inability to maintain a blood glucose >50 mg/dL for: 1) more than 12 hours for infants < 1 year of age; 2) more than 15 hours 1-3 years of age; 3) more than 18 hours over 3 years of age
  • Patients in whom the genetic testing (if available and informative) does not prove diffuse HI disease. Such children might be considered if they have one or more of the following situations:

  • no genetic testing results (e.g., due to insurance denial or parental refusal)
  • negative genetic testing (note: only 75% of mutations may be found with existing technology)
  • no autosomal recessive mutations in ABCC8 or KCNJ11 on the maternal allele
  • no autosomal dominant mutations in ABCC8 or KCNJ11
  • Patients thought to have focal HI disease based on genetic testing or insulinoma based on clinical evaluation and have well-controlled blood glucose levels with any degree of dietary or medical management, BUT the patient and their parent(s) or LAR wishes to proceed with surgery for a possible cure of HI disease.

Exclusion Criteria:

  • Patients who do not have a diagnosis of HI
  • Patients with genetic evidence of diffuse HI
  • Patients who are pregnant
  • Nursing mothers who are unwilling to discontinue breastfeeding their infant for 48 hours after Fluorodopa F 18 injection
  • Patients with a known allergy to Fluorodopa F 18 agent

Study Design

Enrollment

250 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

experimental: Pancreatic Imaging with Fluorodopa F 18

Interventions

Fluorodopa F 18

A dose of Fluorodopa F 18, 3-6 MBq/Kg (0.08-0.16 mCi/kg), will be injected intravenously into the subject under the direct supervision of the radiology sub-investigator. Then, the PET imaging procedure will begin and proceed for up to 70 minutes after injection. An abdominal CT image will be made using intravenous contrast. Both images, PET and CT, will be co-localized by the radiologist for interpretation.

Primary outcome measure

  • Radioactivity of 18F-DOPA following transport [ Time Frame: 1 day ]
  • Accuracy of PET imaging compared to intraoperative pancreatic biopsy in patients with congenital hyperinsulinism [ Time Frame: up to one month ]

Central Contacts and Locations

Central contacts

Deborah Rafferty, PhD

682-303-1363Deborah.Rafferty@cookchildrens.org

Locations

Cook Children's Medical Center

Recruiting

Fort Worth, Texas, United States, 76104

Principal Investigator:

Paul Thornton, MD

More Information

Sponsor

Cook Children's Health Care System

Last update posted

Jul 16, 2024

Last verified

Jul, 2024

Keywords

  • Congenital Hyperinsulinism
  • HI
  • Hypoglycemia
  • FDOPA
  • 18F-DOPA
  • Hyperinsulinism
  • Insulinoma

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Cook Children's Health Care System on 2024-07-16.